Evidence map›Paper›PMID 40914078›Full record

ArticleMolecular pharmacology2025

A machine learning-based analysis method for small molecule high content screening of three-dimensional cancer spheroid morphology.

Vishakha Goyal, Dvir Blivis, Steven A Titus, Misha Itkin, Alexey Zakharov, Kelli Wilson, Natalia J Martinez, Ty C Voss

Abstract read
In one paragraph

Article in Molecular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vishakha GoyalDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Dvir BlivisDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Steven A TitusDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Misha ItkinDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Alexey ZakharovDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Kelli WilsonDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Natalia J MartinezDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.
Ty C VossDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland. Electronic address: ty.voss@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although multiparameter cellular morphological profiling methods and three-dimensional (3D) biological model systems can potentially provide complex insights for pharmaceutical discovery campaigns, there have been relatively few reports combining these experimental approaches. In this study, we used the U87 glioblastoma cell line grown in a 3D spheroid format to validate a multiparameter cellular morphological profiling screening method. The steps of this approach include 3D spheroid treatment, cell staining, fully automated digital image acquisition, image segmentation, numerical feature extraction, and multiple machine learning approaches for cellular profiling. For comparison, we measured the same samples after live-cell microscopy with an endpoint CellTiter-Glo cell viability assay. The combined method characterized 7 reference compounds with previously reported anticancer/cytotoxic properties that induce quantifiably different spheroid morphologies in this assay. The method was then used to screen a library of 925 compounds that are related to kinase signaling pathways. Both unsupervised and supervised machine learning approaches identified compounds that induced morphologies similar to those induced by the reference compounds. We performed a follow-up 16-point concentration response experiment for 3 of these compounds selected from our profiling pipeline and confirmed their phenotype. The morphology-based concentration response for these compounds was also correlated with the CellTiter-Glo endpoint assay. Additionally, the measured morphological phenotypes displayed different enrichment levels of commonly annotated mechanisms of action. Our analysis was able to identify selected mechanisms of action associated with specific phenotypic signatures. Overall, the presented screening and analysis method can distinguish between different spheroid structural changes that are caused by specific candidate anticancer compounds. SIGNIFICANCE STATEMENT: Morphological profiling has become a powerful tool in the field of microscopy for finding distinct mechanisms of action groups and small molecule screening to identify new phenotypes. This study presents new potential mechanisms of action groups for known glioblastoma candidates from the screening library, which is believed to help advance the search for more effective glioblastoma therapies.

Indexed as

Antineoplastic AgentsHigh-Throughput Screening AssaysMachine LearningSmall Molecule LibrariesSpheroids, CellularCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorGlioblastomaHumansAntineoplastic AgentsSmall Molecule LibrariesGlioblastomaHigh content screeningMachine learningMultiparameter cell morphological profilingThree dimensional spheroid

Identifiers

PMID40914078
PMCPMC12597564

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.